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The pathways leading from aberrant Prion protein
(PrP) metabolism to neurodegeneration are poorly
understood. Some familial PrP mutants generate
increased CtmPrP, a transmembrane isoform associ-
atedwithdisease. Inotherdiseasesituations, apoten-
tially toxic cytosolic form (termed cyPrP) might be
produced. However, the mechanisms by which
CtmPrP or cyPrP cause selective neuronal dysfunction
are unknown. Here, we show that both CtmPrP and
cyPrPcan interactwithanddisrupt the functionofMa-
hogunin (Mgrn), a cytosolic ubiquitin ligase whose
loss causes spongiform neurodegeneration. Cultured
cells and transgenic mice expressing either CtmPrP-
producing mutants or cyPrP partially phenocopy
Mgrn depletion, displaying aberrant lysosomal
morphology and loss of Mgrn in selected brain
regions. These effects were rescued by either Mgrn
overexpression, competition for PrP-binding sites,
or prevention of cytosolic PrP exposure. Thus, tran-
sient or partial exposure of PrP to the cytosol leads
to inappropriate Mgrn sequestration that contributes
to neuronal dysfunction and disease.
INTRODUCTION
Mammalian Prion protein (PrP) is a cell-surface GPI-linked glyco-
protein implicated inseveral neurodegenerative diseases including
scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob
disease, and Gerstmann-Straussler-Scheinker disease (Aguzzi
et al., 2007; Collinge and Clarke, 2007). The most extensively
studied aspect of these diseases is their transmissibility via an
unusual agent (termed prion) composed largely, if not exclusively,
of a misfolded isoform of PrP termed PrPSc. Prion propogation is
thought to occur when PrPSc converts the normal cellular form of
PrP (PrPC) into additional copies of PrPSc. Although this explains
how altered protein conformation can form the basis of disease
transmission, relatively little is known about the pathways of
cellular dysfunction that culminate in neurodegeneration in PrP-
associated diseases.1136 Cell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc.Because PrPSc is highly insoluble and aggregation prone, it was
long assumed that its accumulation in the central nervous system
would be intrinsically harmful to neurons. However, this view
appears to be overly simplistic since several experimental para-
digms have partially or fully uncoupled PrP aggregate deposition
from downstream neuropathology (Brandner et al., 1996; Mallucci
etal., 2003;Chesebroetal., 2005). Conversely, several familial PrP
mutations cause neurodegeneration with little or no generation of
PrPSc or transmissible agent (Tateishi and Kitamoto, 1995;
Tateishi et al., 1996; Chiesa et al., 2003). These and other observa-
tions suggest that neurodegeneration might involve different
aspects of PrP metabolism beyond just PrPSc accumulation
(Hetz and Soto, 2006; Chakrabarti et al., 2009), prompting investi-
gation into other isoforms of PrP that might mediate neurotoxicity.
One minor isoform of PrP, termed CtmPrP, spans the membrane
once (at a hydrophobic domain [HD] from residues 112–135)
with the N-terminal domain exposed to the cytosol (Hegde
et al., 1998). Remarkably, both a natural and several artificial
mutants within the HD that lead to even modestly increased
generation of CtmPrP (between 5% and 20% of total PrP) cause
neurodegeneration in transgenic mice (Hegde et al., 1998,
1999). Furthermore, several familial diseases in humans are asso-
ciated with hydrophobicity-increasing mutations in the HD (e.g.,
A117V; Hsiao et al., 1991) that may increase CtmPrP generation
(Hegde et al., 1998). Indirect evidence in transgenic mice
suggests that CtmPrP levels might also be increased (or perhaps
stabilized from degradation) upon PrPSc accumulation (Hegde
et al., 1999). Thus, at least a subset of familial neurodegenerative
diseases, and perhaps also PrPSc-mediated transmissible
diseases, are associated with generation of CtmPrP.
In separate studies, a small proportion of PrP was found to be
degraded in the cytosol by the proteaseome (Yedidia et al., 2001;
Ma and Lindquist, 2001). The observation that improving the effi-
ciency of the PrP signal sequence markedly reduces the propor-
tion of PrP degraded by the proteasome suggested that ineffi-
cient forward translocation into the ER is a major source of
cyPrP (Rane et al., 2004). Interestingly, enforced cyPrP expres-
sion in transgenic mice caused neurodegeneration in a cell-
type-selective manner (Ma et al., 2002). However, the relevance
of this observation to either familial or transmissible disease
caused by PrP has been unclear.
More recently, several observations have suggested an indi-
rect means to potentially link cyPrP production to prion disease
pathogenesis. First, translocation of PrP into the ER is reduced
during ER stress (Kang et al., 2006; Orsi et al., 2006), leading
to increased cyPrP production. Second, ER stress appears to
be an indirect consequence of prion infection and PrPSc accu-
mulation (Hetz and Soto, 2006; Rane et al., 2008). Third, reduced
PrP translocation at levels comparable to that seen during ER
stress was sufficient to cause mild age-dependent neurologic
dysfunction in transgenic mice despite essentially quantitative
degradation of cyPrP (Rane et al., 2008). And finally, proteasome
activity may decline with age (Dahlmann, 2007) and upon PrPSc
accumulation (Kristiansen et al., 2007). Thus it is plausible that by
the combined effects of a weak PrP signal sequence, reduced
PrP translocation during ER stress, and reduced proteasome
activity upon PrPSc accumulation, cyPrP is generated in suffi-
cient amounts during prion disease to be a contributing factor
in neurodegeneration (Rane et al., 2008).
And finally, PrPSc was shown to directly inhibit the proteasome
in vitro (Kristiansen et al., 2007). Because proteasome activity
was observed to be decreased with prion infection in cells and
mice, it was proposed that cytosolic PrPSc inhibits the protea-
some to cause neuronal death during disease pathogenesis.
While it is not yet clear how PrPSc (normally formed in extracel-
lular or endolysosomal compartments) could access the cytosol,
its cytosolic mislocalization was a key point of this model. Thus,
one theme that emerges from the above paradigms of neurode-
generation is the exposure of PrP to the cytosolic environment.
Although only partially or very transiently exposed, this minor
population of PrP could conceivably have adverse conse-
quences for certain cells under certain conditions if it were to
make inappropriate interactions with cellular factors whose func-
tions become compromised. However, candidate interacting
partners for cytosolic PrP are poorly studied and their roles in
disease unknown.
In the context of this hypothesis, the cytosolic protein Mahog-
unin (Mgrn) is especially intriguing. Loss of Mgrn function was
found to cause both the mahoganoid coat color phenotype and
late-onset spongiform neurodegeneration in selected brain
regions (He et al., 2003).The resemblance of Mgrn and prion
disease pathology raised the possibility of a mechanistic relation-
ship. However, a functional connection between Mgrn and PrP
was not immediately apparent. Although Mgrn has E3 ubiquitin
ligase activity, PrP is not a substrate in vitro and does not accu-
mulate in vivo in the absence of Mgrn (He et al., 2003). Neverthe-
less, a growing appreciation that minor populations of PrP are
either partially (in the case of CtmPrP) or transiently (in the case
of cyPrP) exposed to the cytosol during disease led us to consider
the alternative hypothesis that cytosolically mislocalized forms of
PrP might interact inappropriately with Mgrn to inhibit its function.
This would phenocopy Mgrn depletion, leading to region-selec-
tive neurodegeneration. Here, we examine this hypothesis using
in vitro, cell culture, and mouse models.
RESULTS
Experimental Logic
Under normal circumstances, the amounts of CtmPrP and cyPrP
are minor and often transient. Even mutations that favor produc-
tion of these isoforms result in modest increases that, while rele-vant for disease over long time periods in certain cell types,
nonetheless make analysis of potential protein-protein interac-
tions daunting. To circumvent this problem, we initially used arti-
ficial systems that greatly exaggerate the abundance and
stability of Mgrn and cytosolically exposed PrP to explore the
possibility of an interaction between them. This strategy allowed
the evaluation of potential interactions, mapping of interacting
domains, characterization of downstream phenotypes, and
detailed functional analysis in a robust experimental system.
The physiologic relevance of the results from such exaggerated
systems was validated subsequently in cellular and mouse
models that more accurately reflect the disease state.
Interaction of Mgrn with Cytosolic PrP Aggregates
Expression of PrP in the cytosol leads to its rapid degradation by
the ubiquitin-proteasome system. Degradation ensues regard-
less of whether cytosolic PrP is generated by mutation, by dele-
tion of the signal, or by inhibitors of translocation (Ma et al., 2002;
Kang et al., 2006). The very low steady-state levels of cytosolic
PrP therefore make it difficult to assess a potential interaction
with Mgrn in vivo without proteasome inhibitors that could
have many indirect effects. To avoid this, we took advantage
of the serendipitous observation that fluorescent protein (FP)
tagged PrP lacking the N- and C-terminal signals is poorly
degraded and artifactually forms aggregates in nearly all cells
(Figure S1 available online). Such aggregates remained affixed
in the cell upon selective release of freely diffusible cytosolic
contents by digitonin-mediated semipermeabilization of the
plasma membrane. We exploited these observations to develop
an in vivo interaction assay based on coassociation of an
FP-tagged test protein with FP-tagged cytosolic PrP aggregates
(Figure 1A).
Coexpression of red fluorescent protein (RFP) with cyan fluo-
rescent protein (CFP)-PrP40–231 (CFP fused to residues 40–231
of PrP) followed by digitonin permeabilization led to a rapid
and essentially complete loss of RFP signal (within 2–5 min)
from the nucleocytoplasmic compartment (Figures 1B and S1).
By contrast, RFP-Mgrn was partially retained in the cell upon
permeabilization, colocalizing precisely with aggregates formed
by CFP-PrP40–231 (Figures 1C and S1). Coaggregation was seen
with PrP and Mgrn regardless of the FP tags used (we have used
CFP, green fluorescent protein [GFP], and RFP in various combi-
nations), in cells with widely varying expression levels of Mgrn
(spanning at least 20-fold), and with aggregates of various sizes
and morphology (unpublished data). Evidence for an interaction
between RFP-Mgrn and CFP-PrP40–231 could also be observed
without permeabilization, especially in cells where the RFP-
Mgrn was expressed at lower levels and the nonaggregated
population did not confound the imaging (Figures 1C and S1).
Furthermore, the observation that RFP-Mgrn was typically re-
tained in coassociation with the aggregate over an hour after per-
meabilization (unpublished data) suggests that its sequestration
was not rapidly reversible. Importantly, Mgrn sequestration was
specific to PrP aggregates since aggregates formed by a GFP-
tagged Huntingtin (Htt) fragment containing 103 glutamines
failed to coassociate with RFP-Mgrn (Figure 1D). Thus, mislocal-
ized PrP (artificially immobilized into aggregates in this case) can
interact selectively with Mgrn in cultured cells.Cell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc. 1137
Figure 1. Mahogunin Interacts with Cytosolically Exposed PrP
(A) Experimental design to detect a potential interaction between two proteins (red and green), one of which remains immobilized upon semipermeabilization of
the plasma membrane with digitonin.
(B–D) N2a cells cotransfected with the indicated FP-tagged constructs were imaged before (‘‘pre-Dig’’) or after (‘‘post-Dig’’) digitonin semipermeabilization for
10 min. Note that RFP-Mgrn is partially retained with aggregates of CFP-PrP40–231, but not Htt-GFP, after permeabilization.
(E) RFP-Mgrn (red) was transfected into cells stably expressing SA-PrP-Cer or PrP-CFP (green) and analyzed by the digitonin coassociation assay as in (B).
Images before and after permeabilization are shown. RFP-Mgrn is partially retained by SA-PrP-Cer, but not PrP-CFP.
(F) A detergent lysate of normal adult hamster was passed over columns of immobilized BSA or Mgrn, and the bound products (along with different amounts of
input brain lysate) were analyzed by immunoblot for PrP.
(G) RFP-PrP40–231 (top panels) or RFP (bottom panels) was coexpressed in N2a cells with the GFP-Mgrn contructs indicated above each lane. The cells were
fractionated into a cytosolic (soluble) fraction, Triton X-100 wash fraction, and insoluble fraction (4-fold more loaded relative to the other fractions) and immuno-
blotted with anti-GFP (to detect the Mgrn constructs) and anti-RFP (to detect RFP-PrP40–231 aggregates or RFP).1138 Cell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc.
Interaction of Mgrn with Transmembrane PrP
We applied the same semipermeabilization assay to also illus-
trate an interaction between Mgrn and CtmPrP. We first generated
and characterized cell lines expressing FP-tagged wild-type
PrP or SA-PrP, a construct made exclusively in the CtmPrP form
(Figure S2). RFP-Mgrn expressed in these cells was then
analyzed before and after digitonin semipermeabilization. While
RFP-Mgrn was fully extracted from cells expressing wild-type
PrP, it was significantly retained in the SA-PrP cells (Figure 1E).
The retained RFP-Mgrn decorated the plasma membrane and
intracellular membranous structures containing SA-PrP. Thus,
PrP forced into the CtmPrP topology permits an interaction with
Mgrn, whereas wild-type PrP does not (presumably a conse-
quence of its lack of exposure to the cytosol).
Biochemical Validation of PrP-Mgrn Interactions
The key interactions observed between Mgrn and PrP could also
be demonstrated biochemically in two ways. In the first experi-
ment, PrP from a detergent-solubilized crude brain lysate could
be pulled down more efficiently by immobilized recombinant
Mgrn than the immobilized BSA control (Figure 1F). In the second
experiment, we coexpressed RFP-PrP aggregates with different
GFP-Mgrn constructs lacking the N terminus, C terminus, or
RING domain. The cells were then separated into soluble cytosol,
wash, and insoluble fractions. Immunoblotting revealed that
essentially all of the RFP-PrP was found in the insoluble fraction,
consistent with its predominantly aggregated status seen visually
(Figure 1G). Significant GFP-Mgrn, -MgrnDC, and -MgrnDR were
also recovered with the insoluble fraction, while noticeably less
GFP-MgrnDN was recovered (Figure 1G, top panel). Importantly,
none of the Mgrn constructs were seen in the insoluble fraction in
cells lacking PrP aggregates (Figure 1G, bottom panel). Thus,
cytosolically exposed PrP can interact with Mgrn (via its
N terminus; see next section). This interaction is not normally
seen with wild-type PrP (even though it is capable of interacting;
Figure 1F), presumably because the two proteins are in distinct
compartments separated by a membrane barrier.
Mapping the Interaction Domains of Mgrn and PrP
Serial truncations of the cytosolic GFP-PrP construct (all of
which formed cytosolic aggregates; Figure S3) combined with
the digitonin coaggregation assay allowed us to map the key
region of PrP interacting with Mgrn (Figure 2A). Interaction was
abruptly lost upon deletion from residues 84 to 95, when the
last of four identical octapeptide repeats (ORs) is removed
from the construct. An immobilized synthetic peptide encoding
the OR sequence (PHGGGWGQ) could pull-down Mgrn, but
not MgrnDN or GFP, from the cytosol of cells coexpressing these
proteins (Figure 2B). Neither Mgrn nor FP-Mgrn were captured
by control beads lacking peptide (Figure 2C) or beads conju-
gated with irrelevant proteins (such as Protein A or Conconavalin
A; data not shown). Deletion constructs of Mgrn showed that the
N terminus, in particular the region between residues 199 and
251, was involved in the interaction with cytosolic PrP aggre-
gates (Figures 2A, S4A, and 1G). Importantly, Mgrn need not
be functional for this interaction since a construct lacking the
RING domain (termed MgrnDR) still interacts with PrP. Append-
ing only residues 200–250 of Mgrn to an FP was sufficient toallow interaction with cytosolic PrP aggregates (Figure S4B).
Thus, this 50 residue domain within the N-terminal half of Mgrn
interacts with the 8 residue OR sequence, four of which are
present in the N-terminal half of PrP.
Cytosolic PrP Aggregates Lead to Altered Lysosomal
Morphology
The observation that overexpressed FP-Mgrn can interact with
cytosolically exposed PrP raised the possibility that PrP could
similarly sequester endogenous Mgrn to affect its function.
Although the functional role or physiologic substrates of Mgrn
are not known, its depletion by siRNA was shown to affect lyso-
somal morphology (Kim et al., 2007; see Figure 3B). We therefore
used altered lysosome morphology as a phenotypic readout of
functional Mgrn depletion to ask whether cytosolically exposed
PrP would sufficiently influence endogenous Mgrn localization
to at least partially phenocopy a Mgrn depletion.
Antibodies selective to Mgrn (Figure S5A) revealed that unlike
overexpressed Mgrn, endogenous Mgrn is localized in widely
distributed puncta (Figure S5B) that partially colocalize with
markers of the endolysosomal system (Kim et al., 2007; data
not shown). Upon cytosolic GFP-PrP40–231 expression, Mgrn
localization was altered, with clear cosequestration of at least
some Mgrn around the most prominent PrP aggregates
(Figure 3A). It should also be noted that the redistributed Mgrn
that is not with the PrP aggregate also seems to colocalize
Figure 2. Mapping the Interaction Domains in PrP and Mgrn
(A) Deletion constructs of FP-tagged PrP and Mgrn were assayed for interac-
tion as in Figure 1.
(B) Cytosol from cells coexpressing Mgrn, MgrnDN, and GFP were incubated
with octapeptide-conjugated beads. Aliquots of the input and bound (5-fold
excess) fractions were analyzed by immunoblotting with anti-Mgrn and anti-
GFP.
(C) Cytosol from cells coexpressing Mgrn and GFP-Mgrn were incubated with
sepharose beads (‘‘seph.’’) or beads conjugated with the PrP octapeptide
(‘‘pept.’’). Aliquots of the input, unbound, and bound (6-fold excess) fractions
were analyzed by immunoblotting with anti-Mgrn antibody.Cell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc. 1139
Figure 3. Sequestration of Mgrn by Cytosolically Exposed PrP Phenocopies Mgrn Depletion
(A) HeLa cells transfected with the indicated FP-tagged PrP constructs were analyzed by indirect immunofluorescence for endogenous Mgrn. Enlarged views of
the areas within the white boxes (insets) are also shown. Note that the normally puntate pattern of Mgrn expression (as in the presence of wild-type [wt]PrP-CFP
and GFP-PrP95–231) was disrupted in GFP-PrP40–231 expressing cells, where Mgrn is partially sequestered around the aggregates.
(B) HeLa cells transfected with Mgrn siRNAs or irrelevant siRNAs were stained with Lysotracker. Mgrn knockdown causes lysosomal enlargement and clustering.
(C) HeLa cells transfected with GFP, GFP-PrP40–231, or GFP-PrP95–231 were stained to visualize lysosomes as in (B). Enlarged views reveal several larger lyso-
somal structures in GFP-PrP40–231 expressing cells (arrowheads).
(D) Histogram plotting the percentage of total lysosomes (y axis) at each of the sizes indicated on the x axis. Over 120 lysosomal structures from at least 25 cells
are represented for each condition.
(E) HeLa cells transfected with the indicated constructs were analyzed for lysosomal morphology as in (D). The percent of lysosomal structures that are enlarged
(defined as greater than 0.8 mm) is plotted (mean ± standard deviation [SD]). Grey bars indicate PrP constructs that interact with Mgrn.with PrP that is not visible at this detector gain but either is found
in dimmer aggregates or is diffusely cytosolic (unpublished data).
This redistribution was specific to cytosolic PrP aggregates,
given that wild-type PrP, Htt aggregates, and GFP-PrP95–231
aggregates (lacking the octapeptide repeat domains) caused
no noticeable changes in Mgrn localization (Figure 3A and data
not shown). Because endogenous Mgrn appears to normally
be associated tightly with membranes, we could not use selec-
tive digitonin extraction to biochemically separate PrP aggre-
gate-associated Mgrn from normal Mgrn. That notwithstanding,
the striking correlation between altered endogenous Mgrn local-
ization and PrP constructs that in independent experiments
interact with overexpressed FP-Mgrn (e.g., Figures 1 and 2)
argues strongly for a physical sequestration and/or redistribution
by cytosolically exposed PrP.
To assess whether this redistribution might affect Mgrn func-
tion, the lysosomal morphology and distribution in these cells
were visualized with Lysotracker. A change in lysosomal appear-1140 Cell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc.ance toward larger structures (either larger lysosomes, or possibly
clustering) was noted in cells expressing GFP-PrP40–231 aggre-
gates, but not GFP, GFP-Htt aggregates, or GFP-PrP95–231
(Figure 3C and data not shown). A histogram of the diameters of
lysotracker-stained structures (Figure 3D) showed a clear shift in
size: while only5%–10% of lysosomal structures were 0.8mm or
larger in control cells, such enlarged structures represented up to
50% of staining particles in GFP-PrP40–231 aggregate-contain-
ing cells. Importantly, the distribution of lysosomal sizes in both
Htt and GFP-PrP95–231 aggregate-containing cells was similar to
that in control cells, with less than 10% of lysosomes greater
than 0.8mm (Figure 3D). Using this diameter as a cutoff for assess-
ment of ‘‘enlarged’’ lysosomes, we could quantitatively compare
morphologic effects upon expression of different PrP or Mgrn
constructs. Because lysosomes were quantified individually,
this assay has the capacity to discern partial effects (e.g., only
some of the cell’s lysosomes being enlarged) that might be
expected from partial Mgrn depletion.
Figure 4. Lysosomal Morphology Defect Caused by PrP Is Mediated via Mgrn
(A) The effect of several constructs on lysosomal morphology was analyzed in N2a cells and plotted (mean ± SD). The inset shows an anti-Mgrn immunoblot of
HeLa and N2a cells that had or had not been transfected with mouse Mgrn (which serves as a positive control). Mgrn was not detectable in N2a cells. Note that
human Mgrn is slightly larger than mouse Mgrn.
(B) HeLa cells treated with Mgrn siRNAs (upper panels) or irrelevant siRNAs (lower panels) were transfected with GFP-PrP40–231 (left panels) or GFP-PrP95–231
(right panels) and stained with Lysotracker. Two fields for each condition are shown. Note that GFP-PrP40–231 closely phenocopies Mgrn knockdown, and no
additional effect is seen when these two treatments are combined.
(C) HeLa cells cotransfected with GFP-PrP40–231 and either empty vector or Mgrn were stained with Lysotracker. The enlarged lysosomal morphology caused by
PrP aggregates was reverted by coexpression of Mgrn (quantified in D). Transfected (t) and nontransfected (nt) cells are indicated for comparison.
(D) GFP-PrP40–231 was cotransfected with either empty vector, Mgrn, or the catalytically inactive MgrnDR and analyzed for lysosomal morphology in HeLa cells
(mean ± SD). Note that while coexpressing Mgrn rescued the disrupted lysosomal morphology to near wild-type levels, MgrnDR did not. Inset shows comparable
expression levels of Mgrn and MgrnDR in these cells.
(E)GFP-PrP40–231 or GFP-PrP95–231 were cotransfected with Cerulean (Cer; a variant of CFP) or Mgrn200–250-Cerandanalyzed for lysosomal morphology inHeLacells
(mean±SD). Note that Mgrn200–250-Cer rescues the enlarged lysosomal phenotype, presumably by shielding Mgrn-binding sites on GFP-PrP40–231 (see Figure S4B).The Lysosomal Phenotype Caused by cyPrP Aggregates
Results from Mgrn Depletion
The specificity of the lysosomal phenotype to Mgrn depletion
(and not other effects of cytosolic aggregates) was validated in
five ways. First, we could show that the change in lysosomal
morphology correlated precisely with constructs that were
shown in earlier experiments to interact with Mgrn and cause
its redistribution (Figure 3E). Second, we observed that in a cell
type that does not express any endogenous Mgrn (the commonly
used N2a cell line), no changes in lysosomal morphology were
seen upon expression of the same PrP constructs that otherwise
have dramatic effects on lysosomes in HeLa cells (Figure 4A).
Third, the most severe phenotypes seen in cells containing
GFP-PrP40–231 aggregates closely mirrored that seen with siRNA
knockdown of Mgrn, and the two treatments were not further
additive (Figure 4B). Fourth, the lysosomal morphology pheno-
type could be partially reverted by overexpression of functional
Mgrn, but not a catalytically inactive Mgrn lacking the RINGdomain (Figures 4C and 4D). And fifth, overexpression of
Mgrn200–250 tagged with Cerulean (Cer; a variant of CFP), which
interacts with PrP (Figure S4B) and can therefore compete for
endogenous Mgrn, substantially rescued the lysosomal pheno-
type (Figure 4E). Note that this competition also explains the
subtle (but reproducible) partial rescue seen with MgrnDR
(Figure 4D), which typically expresses at more modest levels
than Mgrn200–250-Cer. Considered together, these results show
that cytosolically exposed PrP, whether presented as aggregates
or as a transmembrane protein in the CtmPrP topology, interacts
with Mgrn, influences its localization, and at least partially pheno-
copies Mgrn depletion to cause lysosomal morphology changes.
Relevance of PrP-Mgrn Interaction to Disease-Causing
PrP Mutants
While SA-PrP and GFP-PrP40–231 are quantitatively exposed to
the cytosol (in either the CtmPrP topology or as aggregates),
only a small proportion of total PrP is likely to become exposedCell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc. 1141
Figure 5. Disease-Associated PrPs Lead to Aberrant
Lysosomes in a Mgrn-Dependent Manner
(A) HeLa cells transfected with the indicated PrP constructs
and either functional or inactive (MgrnDR) Mgrn were analyzed
for lysosomal morphology. The percent of enlarged lysosomes
is plotted (mean ± SD).
(B) The indicated PrP constructs were analyzed as in (A),
except that cells were treated with proteasome inhibitor
(10 mM MG132) for 4 hr immediately prior to analysis. The
percent of enlarged lysosomes is plotted (mean ± SD). Note
that while proteasomal inhibition marginally affects the lyso-
somal size for wild-type PrP (wtPrP) cells, there is an increase
in the % of enlarged lysosomes in Ifn-PrP cells that is reverted
by Mgrn, but not MgrnDR.to the cytosol during either inherited or transmissible diseases
caused by PrP. To assess whether situations of only partial PrP
exposure would also have similar effects, we analyzed several
CtmPrP-favoring mutants previously characterized in transgenic
mouse models (Hegde et al., 1998, 1999). These included the
artificial mutants PrP(AV3) and PrP(KH-II), as well as the naturally
occurring human disease mutation PrP(A117V). These con-
structs were coexpressed with either wild-type Mgrn or the cata-
lytically inactive MgrnDR, and the lysosomal morphology was
assessed by quantitative microscopy (Figure 5A). Little or
no change in lysosomal morphology was noted in Mgrn- or
MgrnDR-expressing cells with wild-type PrP, consistent with
the fact that wild-type PrP does not substantially interact with
Mgrn. By contrast, each of the CtmPrP-favoring mutants showed
increased proportions of enlarged lysosomes in the catalytically
inert MgrnDR-expressing cells. Importantly, coexpressing these
same constructs with Mgrn reverted the lysosomal morphology
close to wild-type levels. It should be further noted that these
mutants showed a less dramatic effect on lysosomal morphology
(as judged by % enlarged lysosomes) compared to SA-PrP,
consistent with the fact that they only partially generate CtmPrP.
In another experiment, we asked whether cytosolic PrP gener-
ated as a consequence of reduced PrP translocation could affect
lysosomal morphology in a Mgrn-dependent manner. For this
purpose, we used Ifn-PrP, a construct whose inefficient signal
sequence mimics the lower translocation efficiency seen for
PrP during ER stress (Rane et al., 2008). To stabilize the non-
translocated population of Ifn-PrP, we also briefly inhibited pro-
teasome function (as might also occur during prion infection;
Kristiansen et al., 2007). As with the CtmPrP-favoring constructs,
Ifn-PrP also caused alterations in lysosomal morphology (in
MgrnDR-expressing cells) that were largely normalized in cells
overexpressing Mgrn (Figure 5B). Interestingly, little or no effect
was seen for Ifn-PrP in the absence of proteasome inhibition
where it is degraded highly efficiently (data not shown). Thus,
multiple situations that result in either partial and/or transient
exposure of PrP to the cytosolic environment at elevated levels
lead to alterations in lysosomal morphology that can be rescued
upon coexpression of Mgrn, but not MgrnDR. Importantly, the
constructs used for this analysis (e.g., PrP(A117V) and Ifn-PrP)
lead to more modest phenotypes than the exaggerated situa-
tions with GFP-PrP aggregates or SA-PrP, further supporting
a direct correlation between the extent of cytosolic PrP exposure
and Mgrn dysfunction.1142 Cell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc.Analysis in Transgenic Mice
The observation that PrP and Mgrn are expressed in very similar
patterns within the central nervous system (Figure S6; Lein et al.,
2007) raised the possibility that PrP could influence Mgrn metab-
olism and/or function in mouse models of PrP-mediated disease
involving excessive PrP exposure to the cytosol. To test this
idea, we analyzed the status of Mgrn and lysosomes in trans-
genic mice expressing either human PrP(A117V) or Ifn-PrP
(Hegde et al., 1998; Rane et al., 2008). As controls, we also
analyzed transgenic mice expressing Opn-PrP (Rane et al.,
2008), a previously characterized version of PrP in which its
signal sequence has been replaced with another signal whose
efficiency is slightly higher than wild-type PrP (and hence, does
not show increased CtmPrP or cyPrP).
Mgrn immunostaining revealed widespreadexpression through-
out the CNS (Figure S5D), consistent with previous in situ data
(Figure S6). In Purkinje cells, where expression was especially
prominent, reduction in Mgrn staining was observed selectively
in HuPrP(A117V) and Ifn-PrP mice (Figure 6A). Reduced staining
was also observed in the piriform area of the cortex for the HuPr-
P(A117V) mice but, interestingly, not for the Ifn-PrP mice.
Conversely, in the subiculum, near the hippocampal region,
reduced staining was seen for Ifn-PrP but not HuPrP(A117V)
mice. In the case of Purkinje cells, we could be certain that lack
of staining was not due to the loss of cells, since the cells were
clearly present as judged not only by their characteristic
morphology but also by costaining with the Purkinje cell marker
Calbindin (Figure S7). In the other brain regions, we cannot be
certain whether the reduced staining is due to selective cell loss
or altered expression. It is noteworthy that in the Opn-PrP brain,
no changes in Mgrn staining relative to nontransgenic mice were
observed in any brain region in either young or old mice.
At this point, we do not know whether the reduced staining
represents reduced protein levels (due perhaps to codegrada-
tion of Mgrn upon interaction with PrP) or reduced immunore-
activity due to sequestration. While punctate staining is seen
in cell areas lacking the expected diffuse Mgrn staining pattern,
we cannot be certain that these represent mislocalized or
aggregated Mgrn since similar autofluorescent structures
(seen with preimmune samples) confound the interpretation. It
should be noted that differences in Mgrn levels were not de-
tected by immunoblotting of brain lysates (data not shown),
consistent with the region-selective effects observed by immu-
nohistochemistry.
To examine lysosomal morphology, we analyzed Purkinje cells
by staining for the lysosomal enzyme Cathepsin D (CatD). These
cells were chosen because they were conclusively identifiable,
showed clearly altered Mgrn staining in both HuPrP(A117V)
and Ifn-PrP mice, and had not degenerated. Remarkably, a qual-
itatively obvious increase in CatD staining was seen selectively in
the mice that also showed altered Mgrn staining (Figure 6B).
Figure 6. Alterations in Mgrn and Lysosomes in PrP Mutant Mice
(A) Age-matched brain sections from the indicated transgenic mice (27 months
old) were immunostained with a-Mgrn serum. Three regions of the brain (see
Figure S6) are shown. Note reduced Mgrn staining in Purkinje cells of the cere-
bellum in HuPrP(A117V) and Ifn-PrP mice, in cells of the subiculum region near
the hippocampus of Ifn-PrP mice, and in cells of the piriform cortex of HuPr-
P(A117V) mice. On histologic sections, Mgrn typically displays diffuse cyto-
solic staining with nuclear exclusion (see Figure S5). Note that fixation,
sectioning, and staining of all sections being compared were performed in
parallel, and that imaging conditions were identical among samples.
(B) Age-matched brain sections from the indicated transgenic mice were
immunostained with anti-Cathepsin D antibody. The cerebellum is shown.
Note enhanced accumulation of Cathepsin D in Purkinje cells of the cerebellum
in HuPrP(A117V) and Ifn-PrP mice; this is more than the age-dependent accu-
mulation seen in Opn-PrP mice at 27 months. By contrast to the aged mice,
levels of Cathepsin D expression were comparable in 4-month-old transgenic
mice.Interestingly, this effect was age dependent, as no changes in
CatD staining were observed in any of the mice at 4 months of
age. Thus, mouse models of cytosolic PrP exposure, including
a naturally occurring human disease mutation (HuPrP(A117V)),
result in altered Mgrn expression (or localization) in an age-
dependent and cell type-dependent manner. In at least one
cell type, altered Mgrn expression is correlated with aberrant
lysosomal morphology as was seen in cultured cells.
Rescue from Functional Mgrn Depletion by Preventing
Exposure of PrP to the Cytosol
The data so far indicate that upon cytosolic exposure, PrP can
interact with and functionally titrate Mgrn to cause cellular
dysfunction. However, the forms of PrP implicated in this mech-
anism (CtmPrP and cyPrP) are made at very low levels, even
for disease-causing mutations that favor their generation. This
raised the crucial question of whether such minor populations
of PrP are realistically capable of titrating cellular Mgrn. We
therefore quantified Mgrn in brain and found its level to be
66 pmol per gram total brain protein (Figure S8A). By contrast,
several studies have carefully determined PrP levels in normal
brain to be at least 2 nmol (Pan et al., 1992) and up to 6 nmol
(Bendheim et al., 1988) per gram (i.e., 70–200 mg PrP per
gram total protein). Given that PrP and Mgrn share very similar
patterns of expression in brain (Figure S6), their molar ratio in
most cells will be between30:1 to 90:1. This means that as little
as 1%–2% of PrP exposed to the cytosol may be sufficient to
titrate Mgrn. Importantly, CtmPrP in brain of transgenic mice
expressing wild-type PrP represents 1% of total PrP, while
CtmPrP in PrP(A117V) mice represents6% of total (Figure S8B).
Thus, CtmPrP exceeds Mgrn on a molar basis for PrP(A117V), but
not wild-type PrP.
While the quantification indicates that CtmPrP levels in disease-
causing mutants are sufficient to titrate Mgrn, we sought to test
this directly. For this, we took advantage of the observation that
CtmPrP generation by these mutants depends critically on a slight
but detectable inefficiency of the PrP signal sequence. Thus, re-
placing the PrP signal sequence with a more efficient signal (from
either Prolactin [Prl] or Osteopontin [Opn]) reduces CtmPrP levels
to near wild-type for mutants such as AV3 and A117V (Kim and
Hegde, 2002). Remarkably, Prl-AV3 (the Prl signal fused to the
AV3 mutant of PrP) when expressed in cultured cells does not
cause the Mgrn-dependent enlarged lysosomal phenotype
seen with AV3 (Figure 7A). A similar rescue of the lysosomal
phenotype was seen with Opn-HuPrP(A117V) compared to
HuPrP(A117V) (Figure 7B).
Analysis of transgenic mice overexpressing (at 43 normal;
Table S1) Prl-AV3 and Opn-PrP(A117V) showed that Mgrn levels
remain detectable throughout the life of the animals (Figures 7C
and 7D). Because these mice still contain the pathogenic muta-
tion, differing only in the levels of CtmPrP, this form indeed appears
to be responsible for Mgrn titration and a substantial part of the
neurodegenerative phenotype. Thus, while CtmPrP is only a minor
isoform of PrP, its selective elimination alleviates the Mgrn-
dependent phenotype in cell culture (Figures 7A and 7B) and
Mgrn depletion in mice (Figures 7C and 7D). We therefore
conclude that very small amounts of cytosolically exposed PrP
are sufficient to influence Mgrn function and contribute to disease.Cell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc. 1143
DISCUSSION
This study elucidates a novel interaction between two disease-
causing isoforms of PrP (CtmPrP and cyPrP) and the putative
ubiquitin ligase Mgrn, a protein whose absence leads to spongi-
form neurodegeneration. In cultured cell systems, the interaction
between cytosolically exposed PrP and Mgrn leads to a lyso-
somal morphology phenotype comparable to that seen upon
siRNA-mediated depletion of Mgrn. The relocalization of Mgrn
in these cells and the ability to rescue the altered lysosomal
phenotype with functional Mgrn (but not a catalytically inactive
mutant) argues strongly for functional depletion of Mgrn activity
upon its interaction with PrP. Accordingly, these same cytosoli-
cally exposed PrP constructs had no effect on lysosomal
morphology in a cell type lacking Mgrn. The interaction between
PrP and Mgrn was specific since aggregates formed by another
neurodegeneration-causing protein (Htt) or PrP aggregates lack-
ing the octapeptide repeats neither interacted with Mgrn nor led
to the lysosomal phenotype. Analogous effects on Mgrn immu-
noreactivity and lysosomal morphology were seen in selected
cell types of transgenic mouse models of cytosolically exposed
PrP. One of these mouse models corresponds to a naturally
occurring mutation (PrP(A117V)) associated with Gerstmann-
Straussler-Shienker disease (Hsiao et al., 1991). Remarkably,
the Mgrn depletion caused by this mutant could be rescued by
Figure 7. Selective CtmPrP Reduction Rescues Mgrn
Depletion in Cells and Mice
(A and B) HeLa cells cotransfected with various PrP constructs
and either empty vector, Mgrn, or MgrnDR were analyzed for lyso-
somal morphology. The percent of enlarged lysosomes is plotted
(mean ± SD). The Mgrn-dependent lysosomal phenotypes seen
with PrP(AV3) and HuPrP(A117V) are not seen with Prl-PrP(AV3)
or Opn-HuPrP(A117V).
(C and D) Brain sections from Prl-PrP(AV3) and Opn-HuPrP(A117V)
transgenic mice (lines 6 and 33, respectively) at the indicated ages
were immunostained for Mgrn. Normal levels of Mgrn expression in
Purkinje cells were observed throughout life in both cases, in
contrast to HuPrP(A117V) mice (Figure 6A).
a more efficient signal sequence that acts to selec-
tively minimize PrP exposure to the cytosol. We there-
fore conclude that inappropriate interaction between
cytosolically exposed PrP and Mgrn contributes to
the neurodegenerative phenotype in at least a subset
of diseases associated with aberrant PrP metabolism.
These findings provide a qualitatively new direction for
understanding neurodegeneration caused by PrP and
raise a wide range of questions for future studies.
Among the various naturally occurring diseases
caused by PrP, our findings most directly relate to
two subsets of familial cases. One class of mutations
within the central hydrophobic domain (P105L,
G114V, A117V, G131V, S132I, and A133V) increase
the hydrophobicity of this region and likely lead to
increased generation of CtmPrP (as judged by in vitro
assays; Hegde et al., 1998; Kim and Hegde, 2002).
The other class includes two premature stop codon
mutants (at residues 145 and 160) that seem to display reduced
translocation into the ER, thereby generating increased cyPrP
(Zanusso et al., 1999; Heske et al., 2004). These diseases may
not be transmissible (Tateishi and Kitamoto, 1995; Tateishi
et al., 1996; Hegde et al., 1999) and are not ‘‘prion’’ diseases in
the true sense; rather, they are better viewed as protein-folding
diseases caused by aberrant PrP. Thus, an important question
is how our findings might relate to either other familial PrP-medi-
ated diseases or the transmissible prion diseases. The answer to
these questions awaits further studies but depends on the extent
to which PrP (in particular the N terminus) is ever exposed to the
cytosol during the course of disease pathogenesis.
Due to a slightly inefficient signal sequence, even wild-type
PrP transits through the cytosol to a small (10% of total synthe-
sized PrP) but detectable extent en route to its proteasomal
degradation (Rane et al., 2004; Levine et al., 2005; Ma and Lind-
quist, 2001; Yedidia et al., 2001). Importantly, the molar ratio of
PrP to Mgrn in brain (30:1 to 90:1) means that as little as 2%
of total PrP is equimolar to cellular Mgrn levels. Furthermore,
routing of PrP through the cytosol is increased during ER stress
due to its reduced translocation into the ER (Kang et al., 2006;
Orsi et al., 2006). One implication of these observations is that
there is always a potential opportunity for Mgrn to interact with
PrP, and conditions that enhance this potential might contribute
to neurodegeneration via Mgrn sequestration. This could happen1144 Cell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc.
in any of several ways that might be relevant to both genetic and
transmissible prion diseases.
For example, transmissible prion diseases are accompanied
by both ER stress (Hetz and Soto, 2006; Rane et al., 2008) and
reduced proteasome activity (Kristiansen et al., 2007), possibly
allowing cyPrP to be both elevated and stabilized. Consistent
with such a model, Mgrn was seen to be affected in the Ifn-PrP
transgenic mice designed to mimic the reduced translocation
that might occur during transmissible prion disease. Familial
mutants that act via generation of transmissible prions (e.g.,
E200K or D178N) could act by a similar indirect manner. In addi-
tion, if PrPSc were to ever access the cytosol as has been
proposed (Kristiansen et al., 2007), it too could sequester Mgrn
in much the same way as our artificial cytosolic PrP aggregates.
In other PrP-mediated diseases, the mutations may directly
enhance the interaction with Mgrn, as might be the case with
octapeptide repeat insertions. This could allow even the normally
small amount of cytosolic PrP to contribute to neurodegenera-
tion. Conversely, deletion of repeats seems to attenuate trans-
missible prion disease severity (Flechsig et al., 2000), perhaps
because one adverse downstream event (Mgrn interaction) is
minimized. Intriguingly, mice expressing PrP lacking all ORs do
not show typical spongiform pathology in the CNS upon prion
infection (Flechsig et al., 2000). Thus, via a combination of
different mechanisms, it is plausible that an interaction between
Mgrn and cytosolically exposed PrP may be a contributing factor
in many or all PrP-mediated neurodegenerative diseases, and
not just those involving CtmPrP. Each of these hypotheses merit
further examination to see if cytosolically exposed PrP is indeed
generated and/or stabilized in sufficient amounts to influence
Mgrn localization and function. Because PrP is a very abundant
protein (and often accumulates to many-fold higher levels during
disease), even relatively small proportions of it (a few percent) in
the cytosol would be sufficient to affect the comparatively low
abundance of Mgrn.
Depletion of Mgrn by cytoslically exposed PrP is likely to be
a contributing factor, and not the sole downstream event,
leading to neurodegeneration. This supposition is based on the
fact that PrP-mediated neurodegeneration in mice can be signif-
icantly more severe than simply knocking out Mgrn (where
pathology is observed at 6–12 months; He et al., 2003). However,
there are several possible ways in which an inappropriate inter-
action with PrP is actually more detrimental than a knockout.
One way is if acute or adult-onset depletion of Mgrn precludes
compensatory mechanisms that are otherwise initiated in
a germline knockout. Another is if cytosolic PrP partially code-
pletes factors that associate with Mgrn. Although Mgrn is largely
dispensible, it may associate with other factors whose loss (even
partially) is far more detrimental. One candidate is Tsg101 (Kim
et al., 2007), a key component of the ESCRT machinery involved
in endolysosomal trafficking (Hurley, 2008). By depleting this and/
or other ESCRT factors, the PrP-Mgrn interaction could more
severely influence lysosomal trafficking and cellular function
than simply deleting Mgrn. Thus, while it is likely that most in-
stances of PrP-mediated neurodegeneration will involve multiple
downstream pathways leading to cellular dysfunction, it is none-
theless plausible that the Mgrn interaction could play a much
more central role than might initially appear based on the rela-tively mild phenotype of Mgrn null mice. If this is the case, one
might predict that prion infection of Mgrn null mice would lead
to a much milder phenotype than otherwise expected upon PrPSc
accumulation.
Further insight into the mechanism of neuronal dysfunction
may come from a better understanding of Mgrn function. At
present, the substrates or site(s) of action for this putative ubiq-
uitin ligase are unknown. It has been suggested on the basis of
genetic evidence that Mgrn functions in the same pathway as
Attractin, a cell-surface receptor implicated in melanocortin
signaling (He et al., 2003). In another study, Mgrn was shown
to interact with and ubiquitinate Tsg101 to influence endosomal
trafficking (Kim et al., 2007). This latter result could mean that
Mgrn influences receptor recycling and/or downregulation via
receptor monoubiquitination, an increasingly common traf-
ficking signal in the endolysosomal system (Piper and Luzio,
2007). This would place Mgrn in the ubiquitous and essential
pathway of ubiquitin-dependent trafficking of membrane pro-
teins, consistent with the observed localization pattern on intra-
cellular vesicles. However, its role in endolysosomal pathways
would presumably be nonessential or functionally redundant
since the phenotype of Mgrn null mice is restricted to a small
subset of cells despite rather widespread expression (He
et al., 2003). Such functional redundancy could explain why
despite widespread expression of both cyPrP and CtmPrP
(both within and outside the nervous system), the phenotype
appears to be relatively focal (Hegde et al., 1998; Ma et al.,
2002; Rane et al., 2008). Indeed, in cultured cells that lack
Mgrn expression, neither cyPrP aggregates nor CtmPrP lead to
alterations in lysosomal morphology. Thus, one explanation for
the selectivity of cell death in prion diseases may involve inter-
acting partners, such as Mgrn, whose expression or functional
importance is restricted. This would mean that cyPrP and
CtmPrP are not intrinsically cytotoxic but depend critically on
their cellular context. It will therefore be important not only to
identify other potential interacting partners of cytosolically
exposed PrP but to clearly delineate their expression and
function to elucidate how they might contribute to neurodegen-
eration.
EXPERIMENTAL PROCEDURES
Constructs and Antibodies
All of the PrP-derived constructs have been described before (Hegde et al.,
1998; Rane et al., 2008; Kim and Hegde, 2002; see Supplemental Experimental
Procedures). The FP-PrPx-231 constructs and Mgrn deletion constructs were
generated by standard cloning techniques (see Supplemental Experimental
Procedures). SA-PrP is characterized in Figure S2. GFP-tagged Htt exon 1
containing 103 glutamines was a gift of L. Greene (NIH). Antibodies were
from the following sources: 3F4 and 6D11 mouse monoclonal against PrP
(Signet); Calbindin D28k (Sigma); Cathepsin D (Santa Cruz Biotechnology).
The GFP and RFP antibodies were raised against the full-length recombinant
proteins. Anti-GFP reacts to all GFP-derived FPs (e.g., CFP, Cerulean, YFP,
etc.), but not RFP (data not shown). Rabbit anti-Mgrn was raised against puri-
fied His-tagged full-length Mgrn.
Cell Culture and Imaging
Culture of HeLa and N2a cells, transient transfections, preparation of stable
cell lines, immunofluorescent staining, and fluorescence microscopy of fixed
and live cells were as done previously (Rane et al., 2004, 2008). For quantitativeCell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc. 1145
analyses and comparisons between multiple samples, images were collected
using identical excitation and detection settings within the linear range of the
photomultiplier tube without saturating pixels. Immunohistochemistry was
with minor modifications of earlier methods (Rane et al., 2008; see Supple-
mental Experimental Procedures).
Analysis of Lysosomes
Transfected cells were stained with 500 nM LysoTracker Red DND-99 (Molec-
ular Probes) for 30 min at 37C, rinsed with cold 13 PBS (4C), and fixed with
3.7% formaldehyde in PBS for 10 min at room temperature before imaging.
Random fields of transfected cells (identified by GFP coexpression) were
chosen blindly (without visualization of lysosomal staining), and images were
collected in both the GFP and LysoTracker channels. Five or six fields, each
containing at least four transfected cells, were imaged. Using ImageJ, the lyso-
some images were converted to black and white images using the threshold
function, and the lysosome diameter for each lysosome was manually
measured. The data were tabulated in Microsoft Excel, which was used to
generate the histograms and perform statistical analyses by the Student’s
two-tailed t test.
Semipermeabilization Assays
Semipermeabilization and imaging to detect interactions between proteins
(e.g., Figure 1) were done as described previously (Lorenz et al., 2006; charac-
terized in Figure S1). Biochemical fractionation by selective detergent extrac-
tion has been described (Levine et al., 2005; see Supplemental Experimental
Procedures).
Knockdowns with siRNA
ON-TARGETplus SMARTpool siRNAs against Mgrn and GFP (catalog#
L-022620-00-0005 and D-001300-01-20; Themo Scientific Dharmacon prod-
ucts) were transfected using Lipofectamine 2000 (Invitrogen) following the
manufacturer’s instructions. Constructs to be analyzed were transfected
48 hr after siRNA treatment, and the cells visualized 24 hr later.
Peptide-Binding Assay
A synthetic peptide containing the OR sequence, followed by three glycines
and a cysteine (PHGGGWGQGGGC), was coupled to Sulfo-Link beads
(Pierce). Cytosol for pull-down experiments was generated from 10 cm dishes
of transfected N2a cells. Cell lysate was prepared in 1.5 ml of KHM (110 mM
KAc, 20 mM HEPES, pH 7.2, 2 mM MgAc2) containing 200 mg/ml digitonin.
Debris was removed by centrifugation, and 1250 ml was incubated with 50 ml
of beads (either sepharose or peptide-conjugated sepharose) for 2 hr at
4C. The beads were washed several times with KHM containing 100 mg/ml
digitonin prior to elution with SDS.
Brain Lysate-Binding Assay
Approximately 3 mg purified recombinant Mgrn and BSA fraction V (Sigma)
were immobilized on1 ml CnBr activated sepharose (Amersham Pharmacia).
Two hundred microliters of total hamster brain homogenate (10% w/v)
prepared in PBS containing 0.5% Triton X-100, 0.5% sodium deoxycholate
was clarified by centrifugation and diluted with 1620 ml of KHM containing
100 mg/ml digitonin. This lysate was equally divided and incubated with 50 ml
of each of the immobilized-protein beads for 2 hr at 4C. The beads were
then washed with KHM containing 100 mg/ml digitonin, after which they
were eluted in SDS.
Biochemical Analyses In Vitro and in Cells
In vitro translocation assays, pulse-chase analyses, glycosidase sensitivity,
and immunofluorescence of PrP (and related constructs) employed previously
described methods (Hegde et al., 1998; Rane et al., 2004; Kang et al., 2006).
Transgenic Mice
Ifn-PrP and Opn-PrP transgenic mice have been described (Rane et al., 2008).
Transgenic mice expressing HuPrP(A117V), Opn-HuPrP(A117V), and Prl-
PrP(AV3) mice were generated as described before (Hegde et al., 1999) and
will be characterized in greater detail elsewhere. Transgenic lines 6, 36, and1146 Cell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc.33 of Prl-PrP(AV3), HuPrP(A117V), and Opn-HuPrP(A117V), respectively,
were analyzed (see Table S1).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, one
table, and eight figures and can be found with this article online at http://
www.cell.com/supplemental/S0092-8674(09)00379-1.
ACKNOWLEDGMENTS
We are grateful to N. Rane for providing transgenic mouse tissues and
constructs, E. Whiteman for making the initial Mgrn constructs, Y. Abebe for
expert animal care, L. Greene and H. Lorenz for constructs and sharing unpub-
lished results, G. Patterson for help with microscopy, and L. DaSilva, G. Mar-
dones, and P. Burgos for advice and reagents. This work was supported by the
Intramural Research Program of the NICHD at the National Institutes of Health.
Received: July 11, 2008
Revised: January 13, 2009
Accepted: March 20, 2009
Published: June 11, 2009
REFERENCES
Aguzzi, A., Heikenwalder, M., and Polymenidou, M. (2007). Insights into prion
strains and neurotoxicity. Nat. Rev. Mol. Cell Biol. 8, 552–561.
Bendheim, P.E., Potempska, A., Kascsak, R.J., and Bolton, D.C. (1988). Puri-
fication and partial characterization of the normal cellular homolog of the
scrapie agent protein. J. Infect. Dis. 158, 1198–1208.
Brandner, S., Isenmann, S., Raeber, A., Fischer, M., Sailer, A., Kobayashi, Y.,
Marino, S., Weissmann, C., and Aguzzi, A. (1996). Normal host prion protein
necessary for scrapie-induced neurotoxicity. Nature 379, 339–343.
Chakrabarti, O., Ashok, A., and Hegde, R.S. (2009). Prion protein biosynthesis
and its emerging role in neurodegeneration. Trends Biochem. Sci. Published
online May 15, 2009. 10.1016/j.tibs.2009.03.001.
Chesebro, B., Trifilo, M., Race, R., Meade-White, K., Teng, C., LaCasse, R.,
Raymond, L., Favara, C., Baron, G., Priola, S., et al. (2005). Anchorless prion
protein results in infectious amyloid disease without clinical scrapie. Science
308, 1435–1439.
Chiesa, R., Piccardo, P., Quaglio, E., Drisaldi, B., Si-Hoe, S.L., Takao, M.,
Ghetti, B., and Harris, D.A. (2003). Molecular distinction between pathogenic
and infectious properties of the prion protein. J. Virol. 77, 7611–7622.
Collinge, J., and Clarke, A.R. (2007). A general model of prion strains and their
pathogenicity. Science 318, 930–936.
Dahlmann, B. (2007). Role of proteasomes in disease. BMC Biochem.
8 (Suppl 1), S3.
Flechsig, E., Shmerling, D., Hegyi, I., Raeber, A.J., Fischer, M., Cozzio, A., von
Mering, C., Aguzzi, A., and Weissmann, C. (2000). Prion protein devoid of the
octapeptide repeat region restores susceptibility to scrapie in PrP knockout
mice. Neuron 27, 399–408.
He, L., Lu, X.Y., Jolly, A.F., Eldridge, A.G., Watson, S.J., Jackson, P.K., Barsh,
G.S., and Gunn, T.M. (2003). Spongiform degeneration in mahoganoid mutant
mice. Science 299, 710–712.
Hegde, R.S., Mastrianni, J.A., Scott, M.R., DeFea, K.A., Tremblay, P., Torchia,
M., DeArmond, S.J., Prusiner, S.B., and Lingappa, V.R. (1998). A transmem-
brane form of the prion protein in neurodegenerative disease. Science 279,
827–834.
Hegde, R.S., Tremblay, P., Groth, D., DeArmond, S.J., Prusiner, S.B., and Lin-
gappa, V.R. (1999). Transmissible and genetic prion diseases share a common
pathway of neurodegeneration. Nature 402, 822–826.
Heske, J., Heller, U., Winklhofer, K.F., and Tatzelt, J. (2004). The C-terminal
globular domain of the prion protein is necessary and sufficient for import
into the endoplasmic reticulum. J. Biol. Chem. 279, 5435–5443.
Hetz, C.A., and Soto, C. (2006). Stressing out the ER: a role of the unfolded
protein response in prion-related disorders. Curr. Mol. Med. 6, 37–43.
Hsiao, K.K., Cass, C., Schellenberg, G.D., Bird, T., Devine-Gage, E., Wisniew-
ski, H., and Prusiner, S.B. (1991). A prion protein variant in a family with the
telencephalic form of Gerstmann-Straussler-Scheinker syndrome. Neurology
41, 681–684.
Hurley, J.H. (2008). ESCRT complexes and the biogenesis of multivesicular
bodies. Curr. Opin. Cell Biol. 20, 4–11.
Kang, S.W., Rane, N.S., Kim, S.J., Garrison, J.L., Taunton, J., and Hegde, R.S.
(2006). Substrate-specific translocational attenuation during ER stress defines
a pre-emptive quality control pathway. Cell 127, 999–1013.
Kim, B.Y., Olzmann, J.A., Barsh, G.S., Chin, L.S., and Li, L. (2007). Spongiform
neurodegeneration-associated E3 ligase Mahogunin ubiquitylates TSG101
and regulates endosomal trafficking. Mol. Biol. Cell 18, 1129–1142.
Kim, S.J., and Hegde, R.S. (2002). Cotranslational partitioning of nascent prion
protein into multiple populations at the translocation channel. Mol. Biol. Cell
13, 3775–3786.
Kristiansen, M., Deriziotis, P., Dimcheff, D.E., Jackson, G.S., Ovaa, H., Nau-
mann, H., Clarke, A.R., van Leeuwen, F.W., Menendez-Benito, V., Dantuma,
N.P., et al. (2007). Disease-associated prion protein oligomers inhibit the
26S proteasome. Mol. Cell 26, 175–188.
Lein, E.S., Hawrylycz, M.J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe,
A.F., Boguski, M.S., Brockway, K.S., Byrnes, E.J., et al. (2007). Genome-wide
atlas of gene expression in the adult mouse brain. Nature 445, 168–176.
Levine, C.G., Mitra, D., Sharma, A., Smith, C.L., and Hegde, R.S. (2005). The
efficiency of protein compartmentalization into the secretory pathway. Mol.
Biol. Cell 16, 279–291.
Lorenz, H., Hailey, D.W., and Lippincott-Schwartz, J. (2006). Fluorescence
protease protection of GFP chimeras to reveal protein topology and subcel-
lular localization. Nat. Methods 3, 205–210.
Ma, J., and Lindquist, S. (2001). Wild-type PrP and a mutant associated with
prion disease are subject to retrograde transport and proteasome degrada-
tion. Proc. Natl. Acad. Sci. USA 98, 14955–14960.Ma, J., Wollmann, R., and Lindquist, S. (2002). Neurotoxicity and neurodegen-
eration when PrP accumulates in the cytosol. Science 298, 1781–1785.
Mallucci, G., Dickinson, A., Linehan, J., Klohn, P.C., Brandner, S., and Col-
linge, J. (2003). Depleting neuronal PrP in prion infection prevents disease
and reverses spongiosis. Science 302, 871–874.
Orsi, A., Fioriti, L., Chiesa, R., and Sitia, R. (2006). Conditions of endoplasmic
reticulum stress favor the accumulation of cytosolic prion protein. J. Biol.
Chem. 281, 30431–30438.
Pan, K.N., Stahl, N., and Prusiner, S.B. (1992). Purification and properties of
the cellular prion protein from Syrian hamster brain. Protein Sci. 1, 1343–1352.
Piper, R.C., and Luzio, J.P. (2007). Ubiquitin-dependent sorting of integral
membrane proteins for degradation in lysosomes. Curr. Opin. Cell Biol. 19,
459–465.
Rane, N.S., Yonkovich, J.L., and Hegde, R.S. (2004). Protection from cytosolic
prion protein toxicity by modulation of protein translocation. EMBO J. 23,
4550–4559.
Rane, N.S., Kang, S.W., Chakrabarti, O., Feigenbaum, L., and Hegde, R.S.
(2008). Reduced translocation of nascent prion protein during ER stress
contributes to neurodegeneration. Dev. Cell 15, 359–370.
Tateishi, J., and Kitamoto, T. (1995). Inherited prion diseases and transmission
to rodents. Brain Pathol. 5, 53–59.
Tateishi, J., Kitamoto, T., Hoque, M.Z., and Furukawa, H. (1996). Experimental
transmission of Creutzfeldt-Jakob disease and related diseases to rodents.
Neurology 46, 532–537.
Yedidia, Y., Horonchik, L., Tzaban, S., Yanai, A., and Taraboulos, A. (2001).
Proteasomes and ubiquitin are involved in the turnover of the wild-type prion
protein. EMBO J. 20, 5383–5391.
Zanusso, G., Petersen, R.B., Jin, T., Jing, Y., Kanoush, R., Ferrari, S., Gam-
betti, P., and Singh, N. (1999). Proteasomal degradation and N-terminal
protease resistance of the codon 145 mutant prion protein. J. Biol. Chem.
274, 23396–23404.Cell 137, 1136–1147, June 12, 2009 ª2009 Elsevier Inc. 1147
